Chrianna Bharat
Biographic Data
| ID | 7180902 |
|---|---|
| NAME | Chrianna Bharat |
| GIVEN NAMES | Chrianna |
| FAMILY NAME | Bharat |
| SIGNATURE | BHARAT C |
| AFFILIATIONS | UNSW Sydney |
| ORCID | 0000-0002-9778-0386 |
| VERIFIED | Yes |
| TOTAL WORKS | 12 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 12 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia
Factors Associated With Adult Incarceration Among People With Opioid Use Disorder in New South Wales, Australia
Trends in Opioid Agonist Treatment for Opioid Dependence During Pregnancy
Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use
Trends in prescription opioid analgesic use in Australia from 2015 to 2022
Prescribed opioid analgesic use declined between 2015 and 2022 because of reductions in PBS dispensing claims. A quarter of the reduction in PBS dispensing claims was offset by use outside the PBS. Our findings indicate a significant increase in private use, reasons for which may include accessing opioids not PBS-subsidised and circumventing PBS restrictions for PBS-subsidised opioids. Comparing multiple data sources provides a comprehensive acco…
Prescription opioid use among people with opioid dependence and concurrent benzodiazepine and gabapentinoid exposure
The increased mortality risk associated with benzodiazepines and gabapentinoids among PWOD appear to be reduced when engaged in OAT. A greater focus on encouraging OAT engagement, providing overdose prevention education, and access and coverage of overdose antidotes is necessary to minimise the unintended consequences of medicines use in this population
Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Patterns of OAT have shifted over the last 10-years with buprenorphine (SL/LAI) now the most common OAT used in Australia. The introduction of LAI buprenorphine has expanded OAT access, particularly in non-community pharmacy settings, and in remote areas
Mortality during and after specialist alcohol and other drug treatment
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence
Importance Mortality among people with opioid dependence is higher than that of the general population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence; however, there has not yet been a systematic review on the relationship between OAT and specific causes of mortality. Objective To estimate the association of time receiving OAT with mortality. Data Sources The Embase, MEDLINE, and PsycINFO databases were searched t…
Alcohol use, regular use, disorder and remission from use disorders in Northern Ireland
Background: This study presents prevalence estimates and ages of onset for alcohol use, regular use, use disorders and remission from use disorders in Northern Ireland, and the time for transitioning between these stages.Methods: Data on alcohol use, lifetime history, and remission from alcohol conditions as defined by the DSM-IV were collected using the Composite International Diagnostic Interview.Results: By the age of 17 years 50% of the age c…
The epidemiology of drug use disorders cross-nationally
Cohort Alcohol Use in France and the Transition from Use to Alcohol Use Disorder and Remission
The study aimed to examine the age of onset of stages of alcohol use in the general population, and to estimate the association of cohort use with the probability of transitioning from alcohol use to alcohol use disorder (AUD) and remission. French data (N = 2,894) from the European Study of the Epidemiology of Mental Disorders Survey and collected in 2000 were used. Data on lifetime history of alcohol use and DSM-IV alcohol use disorders, and re…
No prominent works on this page.
Alcohol use, regular use, disorder and remission from use disorders in Northern Ireland
Background: This study presents prevalence estimates and ages of onset for alcohol use, regular use, use disorders and remission from use disorders in Northern Ireland, and the time for transitioning between these stages.Methods: Data on alcohol use, lifetime history, and remission from alcohol conditions as defined by the DSM-IV were collected using the Composite International Diagnostic Interview.Results: By the age of 17 years 50% of the age c…
The epidemiology of drug use disorders cross-nationally
Cohort Alcohol Use in France and the Transition from Use to Alcohol Use Disorder and Remission
The study aimed to examine the age of onset of stages of alcohol use in the general population, and to estimate the association of cohort use with the probability of transitioning from alcohol use to alcohol use disorder (AUD) and remission. French data (N = 2,894) from the European Study of the Epidemiology of Mental Disorders Survey and collected in 2000 were used. Data on lifetime history of alcohol use and DSM-IV alcohol use disorders, and re…
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence
Importance Mortality among people with opioid dependence is higher than that of the general population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence; however, there has not yet been a systematic review on the relationship between OAT and specific causes of mortality. Objective To estimate the association of time receiving OAT with mortality. Data Sources The Embase, MEDLINE, and PsycINFO databases were searched t…
Mortality during and after specialist alcohol and other drug treatment
Prescription opioid use among people with opioid dependence and concurrent benzodiazepine and gabapentinoid exposure
The increased mortality risk associated with benzodiazepines and gabapentinoids among PWOD appear to be reduced when engaged in OAT. A greater focus on encouraging OAT engagement, providing overdose prevention education, and access and coverage of overdose antidotes is necessary to minimise the unintended consequences of medicines use in this population
Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Patterns of OAT have shifted over the last 10-years with buprenorphine (SL/LAI) now the most common OAT used in Australia. The introduction of LAI buprenorphine has expanded OAT access, particularly in non-community pharmacy settings, and in remote areas
Trends in prescription opioid analgesic use in Australia from 2015 to 2022
Prescribed opioid analgesic use declined between 2015 and 2022 because of reductions in PBS dispensing claims. A quarter of the reduction in PBS dispensing claims was offset by use outside the PBS. Our findings indicate a significant increase in private use, reasons for which may include accessing opioids not PBS-subsidised and circumventing PBS restrictions for PBS-subsidised opioids. Comparing multiple data sources provides a comprehensive acco…
Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia
Factors Associated With Adult Incarceration Among People With Opioid Use Disorder in New South Wales, Australia
Trends in Opioid Agonist Treatment for Opioid Dependence During Pregnancy
Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use
Opioid Use Disorder Treatment (8 works) · Substance Abuse Treatment and Outcomes (8 works) · Internal Medicine (7 works) · Medicine (7 works) · Cohort (5 works) · HIV, Drug Use, Sexual Risk (5 works) · Opioid (5 works) · Psychiatry (5 works) · Alcohol (3 works) · Cohort study (3 works)